吉非替尼联合吉西他滨+顺铂治疗晚期非小细胞肺癌患者的疗效及安全性  被引量:2

Efficacy and safety of gefitinib combined with gemcitabine+cisplatin in the treatment of advanced non-small cell lung cancer

在线阅读下载全文

作  者:闫源渊 邢国强 杨怀成 张缓 YAN Yuanyuan;XING Guoqiang;YANG Huaicheng;ZHANG Huan(Department of Pharmacy,the First Hospital of Weinan,Weinan 714000,Shaanxi,China;Department of Oncology,the First Hospital of Weinan,Weinan 714000,Shaanxi,China;Department of Pharmacy,Xi’an Yanliang District People’s Hospital,Xi’an 710089,Shaanxi,China)

机构地区:[1]渭南市第一医院药剂科,陕西渭南714000 [2]渭南市第一医院肿瘤科,陕西渭南714000 [3]西安市阎良区人民医院药剂科,西安7100890

出  处:《癌症进展》2023年第11期1257-1260,共4页Oncology Progress

摘  要:目的探讨吉非替尼联合吉西他滨+顺铂治疗晚期非小细胞肺癌患者的疗效及安全性。方法依据治疗方案的不同将80例晚期非小细胞肺癌患者分为对照组和观察组,每组40例,对照组患者给予吉西他滨+顺铂治疗,观察组患者给予吉非替尼联合吉西他滨+顺铂治疗。比较两组患者的临床疗效、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、糖类抗原19-9(CA19-9)]水平及治疗期间不良反应发生情况。结果观察组患者的客观缓解率、疾病控制率分别为70.00%、95.00%,分别高于对照组患者的47.50%、80.00%,差异均有统计学意义(P<0.05)。治疗后,两组患者血清CYFRA21-1、NSE、CA19-9水平均低于本组治疗前,且观察组患者血清CYFRA21-1、NSE、CA19-9水平均低于对照组,差异均有统计学意义(P<0.05)。观察组患者皮疹、腹泻发生率均明显低于对照组,差异均有统计学意义(P<0.01)。两组患者贫血、恶心呕吐、骨髓抑制、转氨酶升高发生率比较,差异均无统计学意义(P>0.05)。结论晚期非小细胞肺癌患者应用吉非替尼联合吉西他滨+顺铂治疗效果显著,能够明显降低肿瘤标志物水平,减少不良反应,有益于患者预后的改善。Objective To investigate the efficacy and safety of gefitinib combined with gemcitabine+cisplatin in the treatment of advanced non-small cell lung cancer.Method A total of 80 patients with advanced non-small cell lung can-cer were divided into control group(n=40,treatment with gemcitabine+cisplatin)and observation group(n=40,treatment with gefitinib combined with gemcitabine+cisplatin)according to different treatment methods.The clinical efficacy,tu-mor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),neuron specific enolase(NSE),carbohydrate antigen 19-9(CA19-9)]and adverse reactions were compared between the two groups.Result The objective response rate and disease control rate of the observation group were 70.00%and 95.00%,respectively,which were higher than 47.50%and 80.00%of the control group,and the differences were statistically significant(P<0.05).After treatment,the serum levels of CYFRA21-1,NSE,and CA19-9 in the two groups were lower than those before treatment,and the serum levels of CY-FRA21-1,NSE,and CA19-9 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of rash and diarrhea in the observation group were significantly low-er than those in the control group,and the differences were statistically significant(P<0.01).There were no significant dif-ferences between the two groups in the incidence of anemia,nausea and vomiting,bone marrow suppression,and transam-inase increase(P>0.05).Conclusion Gefitinib combined with gemcitabine+cisplatin is effective in the treatment of ad-vanced non-small cell lung cancer,which can significantly reduce the levels of tumor markers,reduce the occurrence of adverse reactions,and improve the prognosis of patients.

关 键 词:非小细胞肺癌 吉非替尼 吉西他滨 顺铂 不良反应 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象